17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Disparities in Cancer-Specific Survival Between Māori and Non-Māori New Zealanders, 2007-2016

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          PURPOSE

          While cancer survival is improving across most developed nations, those improvements are not shared equally within their population. Using high-quality national data, we have reviewed the extent to which cancer survival inequities are persisting for indigenous Māori compared with non-Māori New Zealanders and the extent to which these disparities are driven by deprivation, comorbidity, and stage of disease.

          METHODS

          Incident cases of cancer (2007-2016) were extracted from the New Zealand Cancer Registry and linked to mortality and hospitalization data. Descriptive, Kaplan-Meier, and Cox regression methods were used to compare survival outcomes between Māori and non-Māori.

          RESULTS

          Māori continue to have poorer survival than non-Māori for 23 of the 24 most common causes of Māori cancer death, with the extent of this disparity ranging from 12% to 156%. The magnitude of these disparities varies according to deprivation, comorbidity, and stage. Of note, there was a tendency for survival disparities to be largest among those with no comorbidity.

          CONCLUSION

          Māori continue to experience substantial cancer survival inequities. These observations are in keeping with reports from previous decades, which suggest that these disparities persist despite heightened attention. Reduction of the cancer burden on Māori and achievement of equitable survival outcomes require us to prevent cancer for Māori where we can, diagnose Māori patients early when we cannot, and once diagnosed, deliver equitable care to Māori patients at each step along the treatment path.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Origins of socio-economic inequalities in cancer survival: a review.

          Cancer survival is known to vary by socio-economic group. A review of studies published by 1995 showed this association to be universal and resilient to the many different ways in which socio-economic status was determined. Differences were most commonly attributed to differences in stage of disease at diagnosis. A review of research published since 1995 examining the association of cancer survival with socio-economic variables. An association between socio-economic status and cancer survival has continued to be demonstrated in the last decade of research. Stage at diagnosis and differences in treatment have been cited as the most important explanatory factors. Some research has evaluated the psychosocial elements of this association. Socio-economic differences in cancer survival are now well documented. The explanatory power of stage at diagnosis, although great, should not detract from the evidence of differential treatment between social groups. Neither factor can completely explain the observed socio-economic differences in survival, however, and the importance of differences in tumour and patient factors should now be quantified.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The impact of comorbidity on cancer and its treatment.

            Answer questions and earn CME/CNE Comorbidity is common among cancer patients and, with an aging population, is becoming more so. Comorbidity potentially affects the development, stage at diagnosis, treatment, and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret, or manage comorbidity in the context of cancer, with the result that patients who have comorbidity are less likely to receive treatment with curative intent. Evidence in this area is lacking because of the frequent exclusion of patients with comorbidity from randomized controlled trials. There is evidence that some patients with comorbidity have potentially curative treatment unnecessarily modified, compromising optimal care. Patients with comorbidity have poorer survival, poorer quality of life, and higher health care costs. Strategies to address these issues include improving the evidence base for patients with comorbidity, further development of clinical tools to assist decision making, improved integration and coordination of care, and skill development for clinicians. CA Cancer J Clin 2016;66:337-350. © 2016 American Cancer Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Residence in Rural Areas of the United States and Lung Cancer Mortality. Disease Incidence, Treatment Disparities, and Stage-Specific Survival.

              There is increased lung cancer mortality in rural areas of the United States. However, it remains unclear to what extent rural-urban differences in disease incidence, stage at diagnosis, or treatment explain this finding.
                Bookmark

                Author and article information

                Journal
                JCO Glob Oncol
                JCO Glob Oncol
                go
                go
                GO
                JCO Global Oncology
                American Society of Clinical Oncology
                2687-8941
                2020
                8 June 2020
                : 6
                : GO.20.00028
                Affiliations
                [ 1 ]Cancer and Chronic Conditions Research Group, Department of Public Health, University of Otago, Wellington, New Zealand
                [ 2 ]Waitemata District Health Board, Auckland, New Zealand
                [ 3 ]Southern District Health Board, Dunedin, New Zealand
                [ 4 ]Cancer Society of New Zealand, Wellington, New Zealand
                Author notes
                Jason Gurney, PhD, Cancer and Chronic Conditions Research Group, Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand; Twitter: @publichealthUOW; e-mail: jason.gurney@ 123456otago.ac.nz .
                Article
                2000028
                10.1200/GO.20.00028
                7328125
                32511067
                20e0a82c-d212-482e-8760-4413b0243e5a
                © 2020 by American Society of Clinical Oncology

                Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

                History
                : 28 April 2020
                Page count
                Figures: 5, Tables: 0, Equations: 0, References: 29, Pages: 9
                Categories
                00, Epidemiology
                Original Reports
                Custom metadata
                v1

                Comments

                Comment on this article